Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle Glass

Showing results (91-100 of 125) with videos related to

Pageof 13
Sort By:
The Journal of Clinical Endocrinology and Metabolism|October 9, 2004
Characterization of the endocannabinoid system in early human pregnancyRachel J A Helliwell, Lawrence W Chamley, Katherine Blake-Palmer, et al.
Frontiers in Pharmacology|June 14, 2019
CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor AgonistRichard C Kevin, Lyndsey Anderson, Iain S McGregor, et al.
British Journal of Pharmacology|May 19, 2017
Gα<sub>s</sub> signalling of the CB<sub>1</sub> receptor and the influence of receptor numberDavid B Finlay, Erin E Cawston, Natasha L Grimsey, et al.
ACS Chemical Neuroscience|June 24, 2026
Comprehensive Evaluation of Indazole-Based Synthetic Cannabinoid Receptor Agonists with Aliphatic Tail Groups: In Vitro Activities, Metabolic Stability, and In Vivo PharmacokineticsThuy Nguyen, Vineetha Vasukuttan, Lucas Laudermilk, et al.
Forensic Toxicology|January 18, 2023
Characterisation of AMB-FUBINACA metabolism and CB<sub>1</sub>-mediated activity of its acid metaboliteHunter D J Webb, David B Finlay, Shuli Chen, et al.
Journal of Comparative Psychology (Washington, D.C. : 1983)|December 12, 2024
The effect of delta-9 tetrahydrocannabinol and methamphetamine on sustained attention in the jumping spider (Trite planiceps)Bonnie Humphrey, Michelle Glass, Jonathan Hill, et al.
ACS Chemical Neuroscience|September 13, 2019
Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACADavid B Finlay, Jamie J Manning, Mikkel Søes Ibsen, et al.
Bioorganic & Medicinal Chemistry|May 20, 2021
Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybridsThuy Nguyen, Thomas F Gamage, Ann M Decker, et al.
Pharmacology, Biochemistry, and Behavior|February 22, 2023
The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolismDavid B Finlay, Warwick Mackie, Hunter D J Webb, et al.
Medchemcomm|January 17, 2019
Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1<i>H</i>)-one-3-carboxamide scaffoldAnna G Cooper, Caitlin R M Oyagawa, Jamie J Manning, et al.
Pageof 13

Showing results (91-100 of 125) with videos related to

Sort By:
Pageof 13
The Journal of Clinical Endocrinology and Metabolism|October 9, 2004
Characterization of the endocannabinoid system in early human pregnancyRachel J A Helliwell, Lawrence W Chamley, Katherine Blake-Palmer, et al.
Frontiers in Pharmacology|June 14, 2019
CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor AgonistRichard C Kevin, Lyndsey Anderson, Iain S McGregor, et al.
British Journal of Pharmacology|May 19, 2017
Gα<sub>s</sub> signalling of the CB<sub>1</sub> receptor and the influence of receptor numberDavid B Finlay, Erin E Cawston, Natasha L Grimsey, et al.
ACS Chemical Neuroscience|June 24, 2026
Comprehensive Evaluation of Indazole-Based Synthetic Cannabinoid Receptor Agonists with Aliphatic Tail Groups: In Vitro Activities, Metabolic Stability, and In Vivo PharmacokineticsThuy Nguyen, Vineetha Vasukuttan, Lucas Laudermilk, et al.
Forensic Toxicology|January 18, 2023
Characterisation of AMB-FUBINACA metabolism and CB<sub>1</sub>-mediated activity of its acid metaboliteHunter D J Webb, David B Finlay, Shuli Chen, et al.
Journal of Comparative Psychology (Washington, D.C. : 1983)|December 12, 2024
The effect of delta-9 tetrahydrocannabinol and methamphetamine on sustained attention in the jumping spider (Trite planiceps)Bonnie Humphrey, Michelle Glass, Jonathan Hill, et al.
ACS Chemical Neuroscience|September 13, 2019
Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACADavid B Finlay, Jamie J Manning, Mikkel Søes Ibsen, et al.
Bioorganic & Medicinal Chemistry|May 20, 2021
Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybridsThuy Nguyen, Thomas F Gamage, Ann M Decker, et al.
Pharmacology, Biochemistry, and Behavior|February 22, 2023
The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolismDavid B Finlay, Warwick Mackie, Hunter D J Webb, et al.
Medchemcomm|January 17, 2019
Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1<i>H</i>)-one-3-carboxamide scaffoldAnna G Cooper, Caitlin R M Oyagawa, Jamie J Manning, et al.
Pageof 13